By Deena Beasley June 25 (Reuters) – Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, but remained high at a median of $216,000 due to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
US STOCKS-Wall St set for higher open after Micron revives AI optimism, upbeat economic data
* Futures up: Dow 0.33%, S&P 500 0.84%, Nasdaq 2.38% * Memory chips surge as…
Apple aims for better and more entertainment offerings, executive Cue says
By Hanna Rantala CANNES, France, June 24 (Reuters) - Apple aims to release "better and…
Apple raises prices of MacBooks, iPads as memory costs skyrocket
By Stephen Nellis and Aditya Soni SAN FRANCISCO, June 25 (Reuters) - Apple raised iPad…
